

Lipoxin Receptors

Mario Romano*, Irene Recchia, and Antonio Recchiuti

Department of Biomedical Sciences, Aging Research Center, Ce.S.I., "Gabriele D'Annunzio" University Foundation, Via dei Vestini, 31 66013, Chieti, Italy

E-mail: mromano@unich.it; i.recchia@unich.it; a.recchiuti@unich.it

Received January 22, 2007; Revised June 6, 2007; Accepted July 1, 2007; Published September 1, 2007

Lipoxins (LXs) represent a class of arachidonic acid (AA) metabolites that carry potent immunoregulatory and anti-inflammatory properties, LXA₄ and LXB₄ being the main components of this series. LXs are generated by cooperation between 5-lipoxygenase (LO) and 12- or 15-LO during cell-cell interactions or by single cell types. LX epimers at carbon 15, the 15-epi-LXs, are formed by aspirin-acetylated cyclooxygenase-2 (COX-2) in cooperation with 5-LO. 15-epi-LXA₄ is also termed aspirin-triggered LX (ATL). *In vivo* studies with stable LX and ATL analogs have established that these eicosanoids possess potent anti-inflammatory activities. A LXA₄ receptor has been cloned. It belongs to the family of chemotactic receptors and clusters with formyl peptide receptors on chromosome 19. Therefore, it was initially denominated formyl peptide receptor like 1 (FPRL1). This receptor binds with high affinity and stereoselectivity LXA₄ and ATL. It also recognizes a variety of peptides, synthetic, endogenously generated, or disease associated, but with lower affinity compared to LXA₄. For this reason, this receptor has been renamed ALX. This review summarizes the current knowledge on ALX expression, signaling, and potential pathophysiological role. The involvement of additional recognition sites in LX bioactions is also discussed.

KEYWORDS: arachidonic acid, lipoxin, leukotriene, inflammation, anti-inflammatory eicosanoids, receptor, signaling

LIPOXINS

Biosynthesis

Lipoxins (LXs) represent a class of arachidonic acid (AA) metabolites with unique anti-inflammatory and immunoregulatory properties. The main components of this series are LXA₄ (5*S*,6*R*,15*S*-trihydroxy-7,9,13-*trans*-11-*cis*-eicosatetraenoic acid) and its positional isomer LXB₄ (5*S*,14*R*,15*S*-trihydroxy-6,10,12-*trans*-8-*cis*-eicosatetraenoic acid). In human cells, LX formation occurs mainly via transcellular metabolism, although biosynthesis in single cell types has been reported. Two main routes of LX formation have been described. One involves transcellular exchanges between polymorphonuclear leukocytes (PMNs) and platelets. Receptor-mediated activation of these cell types yields significant accumulation of LXA₄ and LXB₄[1]. This route proceeds through conversion of the 5-LO product leukotriene (LT) A₄, derived from activated PMNs, into LXs by the platelet 12-LO[2]. This enzyme abstracts hydrogen from carbon-13 of LTA₄ and inserts molecular oxygen at carbon-15 to yield a

*Corresponding author.

©2007 with author.

Published by TheScientificWorld; www.thescientificworld.com

delocalized cation. The cation is attacked by water either at carbon-6 to give LXA₄ or at carbon-14 to give LXB₄[3] (Fig. 1). Thus, platelet 12-LO has LX synthase activity[4]. Indeed, studies with recombinant platelet 12-LO showed that this enzyme has a high affinity for LTA₄, comparable to that calculated for AA (apparent $K_m = 7.9 \pm 0.8$ and $6.2 \pm 1.8 \mu M$, respectively), indicating that LX synthase may represent a major activity of platelet 12-LO[4]. *In vivo*, this pathway is likely to occur during coronary angioplasty[5] and following strenuous exercise[6], when interactions between PMNs and platelets have been documented.




FIGURE 1. The 5-/12-LO biosynthetic pathway of LXs (see text for details).

A second route of LX biosynthesis involves the cooperation between epithelial cells and PMNs[7]. The enzymes involved in this pathway are 15- and 5-LO. AA is initially oxygenated by 15-LO to yield 15*S*-hydroxytetraenoic acid (15*S*-HETE). This is converted by 5-LO to a 5*S*,6*S*,15*S*-epoxytetraene intermediate, which is enzymatically transformed into LXA₄ and LXB₄ (Fig. 2). Alternatively, LTA₄ can be converted by 15-LO to the 5*S*,6*S*,15*S*-epoxytetraene and then to LXs. LX generation by this route also occurs in isolated human PMNs[8], eosinophils[9], alveolar macrophages[10], as well as during coincubations of PMNs and eosinophils[9]. LX generation in the respiratory tract may be mainly generated by this pathway[11].




FIGURE 2. The 5-/15-LO pathway of LX biosynthesis (see text for details).

A distinct biosynthetic route yields an additional class of LXs, the 15*R* epimers, also termed 15-epi-LXs. They are generated by aspirin-acetylated cyclooxygenase-2 (COX-2) in cooperation with 5-LO.

COX-2, acetylated by aspirin, metabolizes AA to 15*R*-HETE, instead of prostanoids. 15*R*-HETE is then taken up by PMNs and converted to 15*R*-LXA₄, also termed aspirin-triggered lipoxin (ATL), and 15*R*-LXB₄ by a 5-LO-catalyzed reaction[12]. Biosynthesis of 15-epi-LXs occurs during transcellular exchanges between aspirin-treated endothelial cells and PMNs[12] (Fig. 3), coincubations of rat hepatocytes with nonparenchymal liver cells[13], or of A549 cells and PMNs[14]. Evidence of 15-epi-LX formation *in vivo* has been obtained by measuring urinary levels of ATL in healthy volunteers subjected to aspirin (100 mg/die) treatment for at least 8 days[15]. Also, ATL plasma levels were measured in healthy subjects taking low-dose aspirin daily for 8 weeks[16].




FIGURE 3. Scheme of 15-epi-LXs biosynthesis (see text for details).

Bioactions

LXs and epi-LXs are potent regulators of the immune-inflammatory response. A significant contribution for the understanding of their bioactions derives from the synthesis of stable analogs. In fact, native compounds are rapidly metabolized and inactivated, mainly by monocyte/macrophage. LXA₄ is dehydrogenated by 15-hydroxyprostaglandin dehydrogenase (15-PGDH) to yield 15-oxo-LXA₄. This is reduced by 15-oxoprostaglandin 13-reductase, also known as LTB₄ 12-hydroxydehydrogenase (PGR/LTB₄DH), to form 13,14-dihydro-15-oxo-LXA₄, which is converted by 15-PGDH into 13-14-dihydro-LXA₄. LXB₄ follows a similar metabolic pattern, being converted to 5-oxo-LXB₄, 5-oxo-6,7-dihydro-LXB₄, and to 6,7-dihydro-LXB₄. ω -Oxidation of LXs has been also reported[17].

A number of LX and epi-LX stable analogs have been synthesized[17]. Among these, 15-epi-16-(para-fluoro)-phenoxy-LXA₄ (ATLa) has been widely used *in vivo* and *in vitro*. Notably, the 3-oxa derivatives of ATLa display enhanced chemical stability due to a marked resistance to beta oxidation[18]. These analogs, as well as ATLa, displayed a potent anti-inflammatory activity *in vivo*, even after oral administration, indicating that they may be of therapeutic utility in inflammatory diseases[19].

Cellular Targets

LX and ATL, at nanomolar concentrations, exert potent counter-regulatory actions on cells involved in the immune-inflammatory response. In particular, LX and ATL *inhibit* PMN functions, such as chemotaxis[20], tumor necrosis factor (TNF)- α -induced superoxide anion generation, interleukin (IL)-1 β release and expression[21], lipopolysaccharide (LPS)-induced IL-8 expression and release[22], homotypic aggregation[23], azurophilic degranulation[24], CD11/CD18 expression[23], epithelial and endothelial transmigration[25,26], and nuclear-factor kappa beta (NF- κ B) activation[22]. On the other hand, LX and

ATL *stimulate* a number of monocyte/macrophage responses, i.e., chemotaxis[27], calcium mobilization[28], and nonphlogistic phagocytosis of apoptotic PMNs[29]. In monocytes, LXA₄ and ATL also reduce LPS-stimulated peroxynitrite formation, IL-8 expression and release, and NF-κB activation[22]. Thus, LXA₄ and ATL appear to down-regulate the mounting of inflammatory responses and to up-regulate mechanisms related to the resolution of inflammation. However, these compounds may play a more complex role in the modulation of the immune response. Early data documented the inhibition of NK-dependent cytotoxicity by LXA₄[30]. More recent results show that ATLa can block TNF-α secretion from anti-CD3–stimulated T lymphocytes[31]. Furthermore, LXA₄ regulates dendritic cell migration, IL-12 production[32], and expression of suppressor of cytokine signaling (SOCS)-2[33], thus contributing to the antimicrobial response. Along these lines, LXA₄ inhibits migration and degranulation of eosinophils *in vitro*[34] as well as allergen-induced eosinophil trafficking *in vivo*[35]. Notably, LXs reduce P-selectin expression in endothelial cell, thus controlling the initial phase of leukocyte recruitment to inflammatory sites[36]. In endothelial cells, nanomolar concentrations of ATLa up-regulated the expression of heme oxygenase-1, which is recognized as a main anti-inflammatory pathway[37]. Likewise, LXA₄ amplified heme oxygenase-1 expression in corneal epithelial cells[38]. LXA₄ also regulates fibroblast functions relevant for tissue remodeling in inflammation. In particular, it inhibits IL-1β–induced production of matrix metalloproteinase (MMP)-3 at nanomolar concentrations, while it increases expression of tissue inhibitor of metalloproteinase (TIMP)-1 and 2[39]. Likewise, LXA₄ exerts counteregulatory actions on key inflammatory circuits, namely, peroxisome proliferator-activated receptor-α and CINC-1 in hepatocytes[40]. Moreover, it antagonizes *Pseudomonas aeruginosa*– or TNF-α–induced IL-8 secretion in human epithelial respiratory cells[41,42], highlighting the potential beneficial activity of LXA₄ in cystic fibrosis and acid lung injury (LX and ATL cellular actions are summarized in Table 1).

LX in Disease

Results with a variety of animal models of disease have documented potent anti-inflammatory, proresolution activities of LX and ATL *in vivo*. In the respiratory tract, ATLa reduced methacholin-stimulated bronchoconstriction of mice sensitized with ovalbumin[43]. In this model, it also inhibited leukocyte infiltration, as well as release of T_H2 cytokines. ATLa at subnanomolar/nanomolar concentrations reduced the airway inflammatory response evoked by *P. aeruginosa* in mice[41]. This may be relevant in cystic fibrosis, where *P. aeruginosa* colonization is frequent. Indeed, reduced LXA₄ levels were found in bronchoalveolar lavage (BAL) fluids from patients with cystic fibrosis[41]. The gastrointestinal district represents another preferential target of LX and ATL *in vivo*. LXA₄ protects from aspirin-induced gastric damage in rat[44]. ATLa reduced inflammatory infiltration and protein extravasation in rat peritonitis[45]. In addition, the 3-oxa-ATL analog attenuated the inflammatory reaction in hapten-induced colitis[46], and oral administration to mouse of ATLa at 10 μg/day limited weight loss, hematochezia, and mortality in dextran sodium sulfate–induced colitis[47]. LX and ATL may be beneficial in periodontal disease, as topical application of ATLa dramatically reduced bone destruction and local inflammation in a rabbit model of periodontitis[48]. Topical ATLa also inhibited cutaneous inflammation induced by a variety of inflammatory agents in mouse and guinea pig, although it was less potent than methylprednisolone aceponate[49]. In the mouse eye, topical application of 1 μg LXA₄ or ATLa promoted corneal re-epithelialization after thermal injury or de-epithelialization induced using a corneal rust ring remover, and modulated host-defense mechanisms[50]. Also, treatment of donor bone marrow cells with 100 ng/ml ATLa and i.v. administration of 50 μg/kg ATLa to recipient mouse delayed death by graft-vs.-host disease (GvHD)[51]. This treatment attenuated GvHD-related symptoms, namely, diarrhea, skin lesions, weight loss, and eye inflammation[51]. Thus, results with animal models of disease are encouraging and support the hypothesis that stop signals of inflammation, as LXs and ATL, may be of therapeutic use in human disease (Fig. 4).

TABLE 1
LXA₄ and ATL Most Relevant Bioactions in ALX-Expressing Cells











	Cell Type	Bioactions
	Neutrophils	<ul style="list-style-type: none"> ↓ Chemotaxis, adhesion, transmigration ↓ Degranulation, IL-1β, IL-8, and O₂⁻ production ↓ CD11b/CD18 expression ↓ Adhesion to endothelium ↓ Homotypic aggregation
	Eosinophils	<ul style="list-style-type: none"> ↓ Migration and degranulation ↓ Eotaxin and IL-15 production
	Monocytes/macrophages	<ul style="list-style-type: none"> ↑ Chemotaxis and adhesion to laminin ↑ Nonphlogistic phagocytosis of apoptotic PMNs ↓ Peroxynitrite formation ↓ IL-8 production ↓ NF-κB activation
	T lymphocytes	<ul style="list-style-type: none"> ↓ TNF-α secretion
	Dendritic cells	<ul style="list-style-type: none"> ↓ IL-12 production ↑ SOCS-2 expression
	Epithelial cells	<ul style="list-style-type: none"> ↓ IL-8 release
	Fibroblasts	<ul style="list-style-type: none"> ↓ CTGF-induced proliferation ↓ IL-6, IL-8, and MMP-3 production ↑ TIMP-1
	Renal mesangial cells	<ul style="list-style-type: none"> ↓ PDGF- and LTD₄-induced proliferation

TABLE 2 (continued)

	Endothelial cells	<ul style="list-style-type: none"> ↑ TF expression ↑ PGI₂ formation ↓ VEGF-induced proliferation, adhesion, and migration ↓ P-selectin expression ↑ Heme oxygenase-1 expression
	Hepatocytes	↓ PPARα and CINC-1 expression




FIGURE 4. LX in human disease (see text for details).

ALX, THE LXA₄ RECEPTOR

Identification

To elucidate LX interaction with target cells and intracellular signaling, binding studies with radiolabeled [11,12-³H-LXA₄] were carried out. Specific binding sites were initially recognized in PMNs ($K_d = \sim 0.5$ nM; $\sim 1,800$ sites/cell)[52]; in HL-60 cells differentiated with phorbol 12-myristate 13-acetate (PMA), retinoic acid, or dimethyl sulfoxide (DMSO) ($K_d = \sim 0.6$ nM); and in endothelial cells ($K_d = \sim 11$ nM)[53]. Interestingly, [11,12-³H-LXA₄] binding to endothelial cells was displaced by excess LTD₄ or by the LTD₄ receptor antagonist SKF 104353, indicating that LXA₄ may interact with a LTD₄ receptor in endothelial cells[53]. This observation was later confirmed by Gronert et al.[54], who showed that [³H]-ATLa binds to recombinant cysteinyl leukotriene receptor (CysLT₁) with equal affinity of LTD₄, but it antagonizes LTD₄-induced proinflammatory signaling.

The nature of the LXA₄ specific binding site in PMNs remained elusive, however, although the observation that some intracellular signaling events triggered by LXA₄ were pertussis toxin (PTX) sensitive and that the binding of radiolabeled LXA₄ with PMN granule membrane fractions was regulated by GTPγS[52] suggested that a G-protein coupled recognition site was involved in LXA₄ signaling. A major breakthrough in the identification of the LXA₄ receptor came from the screening for [11,12-³H-LXA₄] binding to orphan G-protein coupled receptors (GPCRs). One plasmid DNA, initially denominated pINF114, conferred to transfected CHO cells specific ³H-LXA₄ binding, with an apparent K_d of ~ 1.7 nM[53]. LXA₄ induced GTP hydrolysis and AA release in transfected cells, and these responses were PTX sensitive[55]. pINF114 was therefore *deorphanized* and recognized as a LXA₄ receptor. A number of independent studies reported the cloning of this receptor, attributing to it a variety of different names. Its sequence is high homologous (69%) with that of the formyl peptide receptor (FPR) and, therefore, it was termed formyl peptide receptor like 1 (FPRL1) by Murphy et al.[56]. It was also named FPRH1[57], FPR2[58], RFP[59], and HM63[60]. The more recent nomenclature of the International Union of Pharmacology denominated this receptor ALX, in view of the evidence that LXA₄ is the most potent endogenous agonist for this receptor[61]. Notably, LXA₄ recognition of ALX is highly stereoselective. For binding and activity, a 15-hydroxyl group, the tetraene structure, the 11,12-*cis*, and the 13,14-double bond within the tetraene are required. The lines of evidence that justify the attribution of the name ALX to this receptor are reviewed in Chiang et al.[62].

The FPRL1/ALX Gene in Human and Mouse

The human FPRL1/ALX gene maps on chromosome 19 at 19q13.3-q13.4[57]. It encompasses 9.60 kb on the direct strand. The gene contains two exons and two gt-ag introns. Alternative splicing produces two different transcripts, 2181 and 2636 bp long, respectively, encoding one protein product. In the mRNA, the 5'UTR encompasses ~ 773 bp, whereas the 3'UTR contains ~ 803 bp followed by the polyA. A variant polyadenylation signal ATTAAA is located ~ 21 bp before the polyA. In one population study with blood donors in North America, no polymorphic variants within the coding reading frame of FPRL1/ALX were detected[63]. The human FPRL1/ALX protein contains 351 residues for a calculated MW of 38.9 kDa, arranged in seven putative transmembrane domains (TMs) with the N-terminus placed on the external side and the C-terminus on the intracellular side. Thus, ALX belongs to the GPCR family.

Human FPRL1/ALX is a member of the FPR gene cluster (FPR, FPRL1, FPRL2) that spans ~ 80 kb on chromosome 19. FPRL1/ALX displays 69% amino acid sequence homology with FPR and 83% with FPRL2. The mouse ALX receptor was cloned by Takano et al. utilizing a spleen cDNA library[64]. This receptor, termed *Lxa4r/Fprl1*, bound radiolabeled LXA₄ with high affinity ($K_d \sim 1.5$ nM) in CHO-transfected cells and transduced anti-inflammatory responses. It is highly expressed in PMNs and its amino acid sequence is 73% identical with the human ALX. Utilizing probes for the human genes, Gao et al. cloned six mouse genes, which form a cluster on mouse chromosome 17 and were denominated *Fprl*

and *Fpr-rs1-5*[65]. Of these genes, *Fpr-rs1* and *Fpr-rs2* displayed the highest homology with FPRL1/ALX. In a separate study, Vaughn et al. identified a clone denominated 8C10, which is highly homologous to *Lxa4r/Fpr11* (89% identity) and identical to *Fpr-rs2*[66]. COS-1 cells cotransfected with 8C10 and *Gα16* cDNA displayed inositol-1,4,5-triphosphate (IP₃) accumulation when exposed to nanomolar concentrations of LXA₄.

A rat LXA₄ receptor was recently cloned[45]. It is expressed in leukocytes, lung, and kidney, and its amino acid sequence is 74% homologous with that of human ALX and 84% homologous with that of the mouse LXA₄ receptor. The rat LXA₄ receptor showed specific binding with [³H]LXA₄ (*K_d* ~5 nM) and inhibited TNF-α-induced NF-κB activity[45].

Thus, a LXA₄ receptor, bearing regulatory functions of the immune-inflammatory response, is maintained across species. The preparation of a transgenic mouse model, engineered for targeted overexpression of human (h)ALX in myeloid cells, greatly contributed to the understanding of the functional role of ALX *in vivo*[67]. The hALX mice displayed a ~80% reduction in PMN infiltration in ear skin after challenging with LTB₄ plus prostaglandin (PG)E₂ and a marked reduction in peritoneal PMN infiltrates in response to zymosan. Remarkably, these responses were observed in the absence of administration of ALX agonists[67]. This observation supports the concept of a predominant anti-inflammatory function of ALX *in vivo*.

Functional Domains

Site-directed mutagenesis of putative phosphorylation residues Ser-236, Ser-237, and Tyr-302, determined sustained phospholipase A₂ and D activation by LXA₄ in CHO-transfected cells, as opposed to the transient activation observed with cells transfected with wild-type ALX[68]. Additional information on LXA₄ recognition domains derives from chimeric constructs. In particular, studies with chimeras ALX/LTB₄ receptor 1 (BLT₁) showed that the seventh TM domain and adjacent regions are relevant for LXA₄ binding and activity[69]. Domains involved in peptide signaling (see section on peptidic ligands) have been also identified. Studies with ALX/FPR chimeras localized a number of such domains within the sixth TM domain and the third extracellular loop[70]. Moreover, interaction sites with a 42 amino acid amyloid β peptide (Aβ₄₂) were localized at the N-terminus and within a stretch between the fourth TM domain and the third intracellular loop[70]. On the other hand, binding of peptides MMK-1 and MHC required extracellular loops[69]. Thus, distinct domains appear to be involved in the recognition of LXA₄ vs. other peptide ligands. This observation may have relevant implications, as ALX activation by peptides can switch responses from anti- to proinflammatory.

Cellular and Tissue Expression

Initially localized in myeloid cells, ALX expression has been observed in a variety of cell types. In particular, PMNs[52], monocytes[71], basophils[72], dendritic cells[73], and T lymphocytes[31] all express ALX, underscoring the pre-eminent role of ALX in the immune-inflammatory response. On the other hand, human intestinal epithelial cells express the full-length sequence of neutrophil ALX[74]. In these cells, ALX mRNA expression was up-regulated by a number of cytokines, IL-13 (10 ng/ml) and interferon (IFN)-γ (1,000 U/ml) being the most potent. Likewise, IL-1β stimulated accumulation of ALX mRNA in human synovial fibroblasts[39]. In addition, PGE₂, generated by acid injury, up-regulated ALX expression in human respiratory epithelial cells[42]. These observations suggest that ALX expression could be transcriptionally regulated, although more direct evidence of ALX transcriptional events is awaited. Interestingly, ALX expression in astrocytoma[75], neuroblastoma[76], and colon cancer cells[74] has been reported. Accordingly, ALX expression in breast, prostate, and ovarian cancer cell lines has been observed (Recchia et al., unpublished observation). These findings suggest that ALX could play a role in cancer proliferation and/or invasion. Finally, ALX appears to be expressed in endothelial

cells[77] and in vascular smooth muscle cells (Recchiuti et al., unpublished observation). Thus, ALX involvement in vascular biology needs to be further elucidated.

In relation to organ distribution of ALX, spleen and lung show high abundance of ALX transcript. Lower levels were observed in heart, liver, and placenta[55]. Cellular expression of ALX is summarized in Table 1.

Peptidic Ligands

Since its identification as the LXA₄ receptor, FPRL1/ALX has been proposed as the receptor for a number of peptides, either of viral/bacterial origin or endogenously generated. Peptide and LXA₄ signaling may be different, accounting for different bioaction profiles. It has been proposed that this feature, i.e., one receptor structure for multiple ligands and functions, could represent a sort of “genomic economy” within the immune system[62]. How this “*promiscuous selectivity*” is achieved remains a crucial issue. Relevant information regarding this point can be found in an elegant study by Chiang et al.[69]. These investigators generated chimeric receptors with sequences from ALX and from BLT₁. These constructs revealed that N-glycosylation is essential for ALX recognition of peptide ligands, but not of LXA₄. Moreover, the third extracellular loop, the seventh TM domain, and COOH terminus of ALX are required for LXA₄ binding, whereas high-affinity binding of peptide ligands needs additional regions[69].

It is noteworthy that the majority of the ALX peptide agonists appear to trigger proinflammatory signaling (see section on signaling), although their biological role is not completely clear.

Annexin 1 (ANXA1) represents an exception to this pattern. A 37-kDa protein, originally described as lipocortin, ANXA1 is a potent phospholipase (PL)_{A2} inhibitor. It has been recently reported that ANXA1 and its related peptide Ac2-26 bind to ALX to limit PMN infiltration *in vivo*[78]. A synergistic effect with ATLa was observed, underscoring the control of more than one anti-inflammatory/proresolution pathway by ALX. Moreover, it has been recently shown that annexin-1 and peptide derivatives are released by apoptotic cells (human PMNs, Jurkatt T lymphocytes, human mesangial cells) to promote phagocytosis of apoptotic PMNs by macrophages, likely via ALX[79]

The coagulation/fibrinolytic system is a relevant component of the immune-inflammatory response. **Urokinase plasminogen activator (uPA)** is a serine protease that activates plasminogen to plasmin and binds with high affinity to a membrane receptor, uPAR (CD87)[80]. Recent studies indicate that uPAR not only functions as a proteinase receptor that facilitates activation of uPA and focuses proteolysis to the cell surface, but also affects migration, adhesion, differentiation, and growth through intracellular signaling[81]. uPAR is formed by three extracellular domains (D1, D2, and D3) and is anchored to the plasma membrane via glycosylphosphatidylinositol. Because uPAR lacks an intracellular domain, the existence of a transmembrane transducer was hypothesized. This transducer was identified as ALX. In fact, a soluble form of uPAR (termed D2D3₈₈₋₂₇₄) bound to ALX and was displaced by a stable LXA₄ analog[82]. D2D3₈₈₋₂₇₄ stimulated cellular chemotaxis *via* ALX. Recently, Mazzieri et al. showed that uPAR requires both integrins and ALX to induce chemotaxis[83]. These findings suggest that ALX may stand at the intersection of different regulatory circuits of the immune-inflammatory response.

The discovery that polypeptides associated with neurodegenerative disorders recognize ALX with affinity ranging from nanomolar to micromolar concentrations has fostered interest in this receptor by investigators from this field.

Serum amyloid A (SAA) is an acute-phase protein whose levels are elevated under chronic or recurrent diseases. On enzymatic cleavage by monocytes and macrophages, SAA can generate amyloidogenic fragments and then amorphous fibrillary deposits, leading to amyloidosis[84]. SAA binds to ALX ($K_d = 45$ nM), stimulates chemotaxis of mononucleated phagocytes and PMNs[85], IL-8 secretion *via* NF- κ B, extracellular signaling regulated kinase (ERK) 1/2, and p38 MAPK activation[86].

The **A β ₄₂** protein, the fragment of the amyloid precursor protein that represents the major component of senile plaques in Alzheimer’s disease (AD) patients, also binds and activates ALX and its mouse

counterpart, FPR2, inducing chemotaxis and production of oxygen reactive species in mononuclear phagocytes and microglial cells[87]. Notably, ALX-A β ₄₂ complexes are internalized in macrophages leading to formation of fibrils[88].

The short, 21 amino acid, fragment *PrP*₁₀₆₋₁₂₆ of human prion protein also forms fibrils *in vitro* and stimulates release of proinflammatory cytokines in monocytes and microglia[89]. Le et al. reported that PrP₁₀₆₋₁₂₆ stimulates release of proinflammatory cytokines from monocytes through activation of ALX[90]. On the other hand, ALX has been identified as the receptor for the neuroprotective peptide, *humanin (HN)*, a 24 amino acid polypeptide, encoded by a gene cloned from an apparent normal region of the AD brain[91]. ALX activation by HN results in suppression of A β ₄₂-induced cytopathic effects in neuroblast cells[76]. Collectively, these data suggest that ALX may have a complex role in amyloidosis and that selective stimulation of the anti-inflammatory signaling of ALX may be beneficial in this setting.

Additional endogenously generated peptides bind and activate ALX; in particular, the *MHC binding peptide*, which derives from mitochondrial NADH dehydrogenase subunit 1 and binds ALX with high affinity ($EC_{50} < 1$ nM). This peptide is a potent necrosis inducer, and stimulates neutrophil chemotaxis[69] and macrophage-mediated phagocytosis of PMNs[92]. Antimicrobial peptides represent an important component of the innate immune system, being involved in the regulation of the inflammatory response. *LL37* is a cleavage fragment of neutrophil cathelicidin, which is released into injured tissues. It stimulates angiogenesis, promoting wound neovascularization through activation of ALX on endothelial cells[77]. Notably, ATLa inhibited vascular endothelial growth factor (VEGF)-induced neovascularization in a granuloma *in vivo* model[93]. Thus, multiple signals of the immune-inflammatory-related neovascularization appear to converge on ALX.

A novel N-terminally truncated form of β -chemokine, *CK β 8-1*, was also found to bind ALX, and induced $[Ca^{2+}]_i$ and chemotaxis in PMNs[94]. Interestingly, *temporin A*, a natural antimicrobial peptide isolated from the skin secretions of *Rana temporaria*, recognizes ALX, inducing recruitment of PMNs and monocyte/macrophages in mice *in vivo*[95]. This observation lends further support to the concept that ALX is a key regulator of the trafficking of immune-inflammatory cells during antimicrobial host-response.

Pathogens-derived peptides appear to interact with ALX in the micromolar range of EC_{50} ; among these, some HIV-1 envelope proteins (e.g., T20, T21, N36, V3, and F peptide), bacterial proteins (Hp2-20 from *Helicobacter pylori*), and N-formyl peptides (fMLF)[96,97]. The biological significance of such interactions remains to be fully understood.

The early assumption that formyl group at N-terminus of peptidic sequence was essential for optimal receptor recognition has been challenged by the finding that a large number of *synthetic peptides*, screened from a random library, are able to activate ALX (and, in some cases, FPR). For instance, WKYMVm and MMK-1 are very potent activators of ALX (EC_{50} in the nanomolar range). On the other side, peptides that antagonize ALX signaling have been identified; in particular, WRW blocked at micromolar concentrations, $[Ca^{2+}]_i$ mobilization induced by WKYMVm, MMK-1, A β ₄₂, as well as superoxide generation and chemotactic migration in PMNs exposed to A β ₄₂[98]. This peptide also inhibited A β ₄₂ internalization in human macrophages. Characteristics of ALX ligands are summarized in Table 2

Other Nonpeptidic ALX Agonists

Using a cell-based assay in a high-throughput screening, a pyrazolone derivative with potent ALX agonist activity was identified[99]. This compound showed anti-inflammatory activity in a mouse model either by topical application or oral administration, although it was less potent than 16-phenoxy-LXA₄ or dexamethasone. This finding opens a new avenue of pharmacological investigation for the synthesis of more potent ALX agonists with anti-inflammatory activity.

Signaling

Accumulating evidence indicates that ALX signaling is cell and agonist specific. This is not surprising because GPCRs can be coupled to several G-proteins, and activate different second messengers and downstream signaling pathways. In the case of ALX, the variety of peptide agonists identified, in addition to LXA₄, makes the analysis of signaling more complex. The emerging scenario is that ALX is a peculiar receptor capable of switching responses from anti- to proinflammatory in relation to the activating agent. Thus, LXA₄, ATL, and some peptides trigger potent anti-inflammatory signaling and bioactions, whereas a number of endogenous or disease-associated peptides stimulate proinflammatory events. The question is: Which event predominates and when? One important consideration is that LXA₄ and ATL are the most potent ALX agonists known. They are active in the nanomolar range, as opposed to the majority of peptides,

TABLE 3
Characteristics of ALX Agonists

Ligand	ALX	
	EC ₅₀	K _d
LXA ₄ and ATL		1.7 nM
Bacterial-derived peptides		
fMLF		>1 μM
Hp2-20	300 nM	
Nonformylated peptides		
Annexin 1		>900 nM
D2D3 uPAR fragment	0.1 nM	83 nM
SAA		45 nM
Aβ ₄₂	1.5 μM	
PrP ₁₀₆₋₁₂₆	10 μM	
HN	3.5 μM	
MHC binding peptide		1 nM
LL-37	5 μM	
CKβ8-1	1 μM	
F2L	>1 μM	
Temporin A	~2 μM	
HIV-envelope peptides		
T20		
T21	500 nM	
N36	10 μM	
F peptide	10 μM	
V3 peptide	1.5 μM	
Synthetic peptides		
WKYMVm	75 pM	
MKK-1	2 nM	
WRW	1–10 μM	

which activate ALX at micromolar concentrations. Moreover, transgenic mice overexpressing ALX in myeloid cells are more resistant to zymosan-induced peritonitis and produce less inflammatory exudates[67]. Thus, it is likely that, *in vivo*, the anti-inflammatory properties of ALX may predominate, at

least during physiological host-responses. This does not exclude that in pathological conditions, the accumulation of disease-related peptides, i.e., SAA, A β_{42} , gp120, may overtake LXA $_4$ biosynthesis and trigger proinflammatory ALX signaling. The Janus-like aspect of ALX can be synthesized by the observation that in the brain, ALX can be activated by A β_{42} [87], which damages neuronal cells and is related to AD, but also by HN, which protects neuronal cells from damage by A β_{42} [76]. Disease may occur when equilibrium is broken.

Intracellular Calcium

Increases in [Ca $^{2+}$] $_i$ are induced by LXA $_4$ and ATL, as well as by peptide agonists, both in myeloid cells and in ALX transfected cells (Fig. 5). In monocytes, LXA $_4$ -induced [Ca $^{2+}$] $_i$ increase derives from both




FIGURE 5. Intracellular signaling of ALX. Positive agonists are in the blue boxes, inhibitors are in the red boxes (see text for details).

intracellular mobilization and external influx[28], suggesting that ALX is coupled with membrane Ca $^{2+}$ channels and with IP $_3$ generation. Indeed, accumulation of IP $_3$ in LXA $_4$ -stimulated COS-1 cells cotransfected with mouse ALX and G α_{16} has been documented[66]. LXA $_4$ also induced [Ca $^{2+}$] $_i$ increase in ALX-expressing human respiratory epithelial cells[100]. [Ca $^{2+}$] $_i$ transients were suppressed by thapsigargin, but were left unchanged by EGTA, indicating that release from thapsigargin-sensitive intracellular stores is mainly involved. In these cells, LXA $_4$ induced sustained Cl $^-$ secretion.

AA Release

LXA₄ stimulates release of AA in PMN, differentiated HL-60 cells, and also in ALX-transfected CHO cells[53,55]. In ALX-transfected cells, AA release was maximal after three to five exposures to 10⁻⁹ M LXA₄. AA release in PMNs was also induced by the peptide WKYMVM[101] (Fig. 5).

Phospholipase D

In PMN and retinoic acid-differentiated HL-60 cells, LXA₄ activates phospholipase D (PLD) in a biphasic mode, with a first peak of activity at 10⁻⁹ M and a second peak at 10⁻⁷[53]. Interestingly, the first peak of activity was inhibited by PTX, whereas the second was blocked by staurosporine, indicating that in addition to G-proteins, protein kinase C (PKC) may be involved in ALX signaling. A PKC-dependent activation of PLD was observed in PMN stimulated with the ALX peptide agonist WKYMVM[101] (Fig. 5).

Polyisoprenyl Phosphate

In PMNs, LXA₄ and ATL reversed the decrease in presqualene diphosphate levels evoked by LTB₄. Thus, they promoted the presqualene diphosphate anti-inflammatory pathway, documented by inhibition of superoxide anion generation and PLD activity[102].

Kinases

The ERK pathway can be either activated or inhibited following engagement of ALX agonists. ERK phosphorylation was induced in PMNs by the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP)27, in conjunction with CD11b up-regulation and chemotactic migration[103]. WKYMVM also induced ERK phosphorylation in PMNs[101]. This was associated with c-Jun NH₂-terminal kinase phosphorylation and O₂⁻ generation. On the contrary, nanomolar concentrations of ALTa inhibited the anti-CD3 antibody-mediated activation of ERK and secretion of TNF-α in human T lymphocytes[31]. In human lung fibroblasts, LXA₄ down-regulated ERK as well as PI3K/Akt activation by connective tissue growth factor, resulting in reduced proliferation[104] (Fig. 5). The involvement of ALX was confirmed with overexpression experiments. Thus, proinflammatory ALX agonists may turn ERK on, whereas anti-inflammatory ligands, such as ATLa, turn it off. This clearly illustrates the bimodal function of ALX.

Protein kinase A (PKA) activation occurs during LXA₄-induced phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. This key mechanism of inflammation resolution is associated with rearrangement of F-actin filaments, also involving the small GTPases RhoA and Rac[105]. Along these lines, ATLa inhibited VEGF-induced SAPK/p38 activation and focal adhesion kinases (FAK) clustering in endothelial cells, blocking cell growth, adhesion, and migration[106]. Thus, ALX controls proangiogenic responses that may be relevant in a variety of pathological conditions, including neoplasia, diabetic retinopathy, myocardial infarction, and atherosclerosis.

NF-κB

NF-κB is a key regulator of the inflammatory response. A number of reports have documented NF-κB modulation by ALX agonists. Again, it is striking to denote NF-κB activation by proinflammatory ALX agonists and inhibition by anti-inflammatory agonists, confirming the dual immunoregulatory potential of

this receptor. In human leukocytes, LXA₄ and ATL markedly inhibited NF-κB and activator protein-1 (AP-1) induced by LPS, resulting in reduced IL-8 mRNA expression and protein secretion[22]. Likewise, in a model of inflamed gastrointestinal epithelium, microarray gene expression profile analysis revealed that ALX activation by LXA₄ attenuated NF-κB-induced expression of several proinflammatory genes in response to *Salmonella typhimurium*[47]. A direct evidence of the inhibitory action of LXA₄-activated ALX on NF-κB activity was obtained using HeLa cells transfected with an ALX cDNA[47]. Along these lines, using CHO cells stably transfected to express human ALX together with the promoter of human IL-8, Sodin-Semrl et al. demonstrated that the NF-κB pathway is the main mechanism involved in LXA₄-elicited down-regulation of this cytokine[107]. Consistently, using embryonic HEK293 cells expressing both the recombinant human ALX and the NF-κB responsive element (NRE)-luciferase vector, Devchand et al. assessed LXA₄-mediated inhibition of TNFα-induced NF-κB activation[67]. On the other side, SAA activated NF-κB in human PMNs, inducing IL-8 secretion. This effect was better observed in HeLa cells overexpressing ALX[86] (Fig. 5).

SOCS-2

LXA₄ up-regulates SOCS-2 expression, *in vivo* and *in vitro*[33] (Fig. 5). This observation highlights the immunoregulatory properties of LXA₄ in host defense. In fact, SOCS-2-deficient mice have an exuberant immune response, with an uncontrolled production of cytokines and leukocyte infiltration, a greater mortality, and impaired bacteria clearance[33].

ADDITIONAL LXA₄ RECOGNITION SITES

The possibility that LXA₄ may interact with multiple intracellular sites was postulated in initial binding studies with radiolabeled LXA₄. Specific binding was in fact localized in PMN granule- and nuclear-enriched fractions[52]. It has been reported that LXA₄ binds to the transcription factor termed Ah receptor (AhR) in Hepa-1 cells[108]. The specific binding is associated with transition of AhR into an active dioxin response element (DRE)-binding state and concentration-dependent increment in mRNA of *CYP1A1*, which is a recognized molecular target of AhR[108]. Interestingly, AhR is required for LXA₄-induced up-regulation of SOCS-2 and inhibition of IL-12 release in mouse splenic dendritic cells[33].

On the other hand, LXA₄ interaction with CysLT receptors has been clearly documented. Early studies showed LXA₄ competition for radiolabeled LTD₄ in mesangial and endothelial cells[109] as well as displacement of radiolabeled LXA₄ by molar excess of LTD₄ or of a CysLT antagonist[53]. These results were confirmed by more recent investigation showing that ATLa and LTD₄ competed with equal affinity (IC₅₀ = ~0.7 nmol/l) for [³H]-LTD₄ binding to recombinant endothelial-type CysLT₁ receptor expressed in COS-7 cells[54]. Consistently, ATLa and LTD₄ competed for [³H]-ATLa binding (IC₅₀ = ~0.1 and 0.9 nmol/l, respectively). Displacement of radiolabel was not observed with 6*S*-LXA₄, indicating that the *rectus* chirality at carbon 6, shared by LTD₄ and ATLa, is crucial for CysLT₁ receptor recognition. Thus, competition at the receptor level represents the main mechanism of LXA₄ counter-regulatory actions on LTD₄-induced inflammatory events, such as vascular leakage. Therefore, LXA₄ may be also regarded as a CysLT₁ antagonist. LXA₄ interactions with CysLT receptors may be, however, more complex. In mesangial cells, LXA₄ counteracts LTD₄-induced proliferation and activates ERK and p38[110]. However, activation of ERK was insensitive to PTX, whereas activation of p38 was blocked by PTX and by the LTD₄ receptor antagonist SKF 104353. Together, these findings suggest that additional LXA₄ recognition sites may exist.

LXB₄ shares a number of anti-inflammatory bioactions with LXA₄. However, it does not compete for ³H-LXA₄ binding, both with PMNs or ALX-transfected cells. This may be an indication that LXB₄ recognizes receptor(s) other than ALX, yet to be discovered.

CONCLUSIVE REMARKS

LXs are emerging as key endogenous stop signals of inflammation. The identification of the LXA₄ receptor, ALX, has represented a significant advance for the understanding of the molecular mechanisms involved in LX anti-inflammatory actions. The great interest in ALX is justified by the fact that ALX appears to regulate host-response and resolution. A number of anti-inflammatory mediators, endogenously generated and pharmacologically induced (aspirin/ATL, corticosteroids/annexin1), appear to signal through this receptor. ALX, however, can also convey proinflammatory signals, *in vitro*, when activated by disease-related peptides (neurodegeneration, HIV infection). Animal studies and analysis of ligand affinity indicate that under physiological circumstances, the anti-inflammatory properties of ALX are predominant. Less is known on ALX in human disease. Are altered expression and/or function of this receptor associated with the development of inflammatory disorders? Given the documented possibility to design ALX agonists with selective anti-inflammatory activity, this receptor may represent a molecular target to be exploited for innovative pharmacological approaches to inflammation-based disorders.

REFERENCES

1. Fiore, S. and Serhan, C.N. (1990) Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. *J. Exp. Med.* **172**, 1451–1457.
2. Romano, M. and Serhan, C.N. (1992) Lipoxin generation by permeabilized human platelets. *Biochemistry* **31**, 8269–8277.
3. Sheppard, K.A., Greenberg, S.M., Funk, C.D., Romano, M., and Serhan, C.N. (1992) Lipoxin generation by human megakaryocyte-induced 12-lipoxygenase. *Biochim. Biophys. Acta* **1133**, 223–234.
4. Romano, M., Chen, X.S., Takahashi, Y., Yamamoto, S., Funk, C.D., and Serhan, C.N. (1993) Lipoxin synthase activity of human platelet 12-lipoxygenase. *Biochem. J.* **296**, 127–133.
5. Brezinski, D.A., Nesto, R.W., and Serhan, C.N. (1992) Angioplasty triggers intracoronary leukotrienes and lipoxin A₄. Impact of aspirin therapy. *Circulation* **86**, 56–63.
6. Gangemi, S., Lucioti, G., D'Urbano, E., Mallamace, A., Santoro, D., Bellinghieri, G., Davi, G., and Romano, M. (2003) Physical exercise increases urinary excretion of lipoxin A₄ and related compounds. *J. Appl. Physiol.* **94**, 2237–2240.
7. Serhan, C.N. (1997) Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? *Prostaglandins* **53**, 107–137.
8. Chavis, C., Vachier, I., Chanez, P., Bousquet, J., and Godard, P. (1996) 5(S),15(S)-dihydroxyecosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. *J. Exp. Med.* **183**, 1633–1643.
9. Serhan, C.N., Hirsch, U., Palmblad, J., and Samuelsson, B. (1987) Formation of lipoxin A by granulocytes from eosinophilic donors. *FEBS Lett.* **217**, 242–246.
10. Levy, B.D., Romano, M., Chapman, H.A., Reilly, J.J., Drazen, J., and Serhan, C.N. (1993) Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. *J. Clin. Invest.* **92**, 1572–1579.
11. Lee, T.H., Crea, A.E., Gant, V., Spur, B.W., Marron, B.E., Nicolaou, K.C., Reardon, E., Brezinski, M., and Serhan, C.N. (1990) Identification of lipoxin A₄ and its relationship to the sulfidopeptide leukotrienes C₄, D₄, and E₄ in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. *Am. Rev. Respir. Dis.* **141**, 1453–1458.
12. Claria, J. and Serhan, C.N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. *Proc. Natl. Acad. Sci. U. S. A.* **92**, 9475–9479.
13. Titos, E., Chiang, N., Serhan, C.N., Romano, M., Gaya, J., Pueyo, G., and Claria, J. (1999) Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4). *Am. J. Physiol.* **277**, C870–877.
14. Claria, J., Lee, M.H., and Serhan, C.N. (1996) Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. *Mol. Med.* **2**, 583–596.
15. Fiorucci, S., Santucci, L., Wallace, J.L., Sardina, M., Romano, M., del Soldato, P., and Morelli, A. (2003) Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 10937–10941.
16. Chiang, N., Bermudez, E.A., Ridker, P.M., Hurwitz, S., and Serhan, C.N. (2004) Aspirin triggers antiinflammatory 15-epi-lipoxin A₄ and inhibits thromboxane in a randomized human trial. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 15178–

- 15183.
17. Romano, M. (2006) Lipid mediators: lipoxin and aspirin-triggered 15-epi-lipoxins. *Inflamm. Allergy. Drug Targets* **5**, 81–90.
 18. Guilford, W.J., Bauman, J.G., Skuballa, W., Bauer, S., Wei, G.P., Davey, D., Schaefer, C., Mallari, C., Terkelsen, J., Tseng, J.L., Shen, J., Subramanyam, B., Schottelius, A.J., and Parkinson, J.F. (2004) Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. *J. Med. Chem.* **47**, 2157–2165.
 19. Romano, M. (2005) Lipoxin analogs and lipoxin formation in vivo. *Prostaglandins Leukot. Essent. Fatty Acids* **73**, 239–243.
 20. Serhan, C.N., Maddox, J.F., Petasis, N.A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H.R., Colgan, S.P., and Madara, J.L. (1995) Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. *Biochemistry* **34**, 14609–14615.
 21. Hachicha, M., Pouliot, M., Petasis, N.A., and Serhan, C.N. (1999) Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. *J. Exp. Med.* **189**, 1923–1930.
 22. Jozsef, L., Zouki, C., Petasis, N.A., Serhan, C.N., and Filep, J.G. (2002) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 13266–13271.
 23. Fiore, S. and Serhan, C.N. (1995) Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. *Biochemistry* **34**, 16678–16686.
 24. Gewirtz, A.T., Fokin, V.V., Petasis, N.A., Serhan, C.N., and Madara, J.L. (1999) LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation. *Am. J. Physiol.* **276**, C988–994.
 25. Colgan, S.P., Serhan, C.N., Parkos, C.A., Delp-Archer, C., and Madara, J.L. (1993) Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. *J. Clin. Invest.* **92**, 75–82.
 26. Fierro, I.M., Colgan, S.P., Bernasconi, G., Petasis, N.A., Clish, C.B., Arita, M., and Serhan, C.N. (2003) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. *J. Immunol.* **170**, 2688–2694.
 27. Maddox, J.F. and Serhan, C.N. (1996) Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. *J. Exp. Med.* **183**, 137–146.
 28. Romano, M., Maddox, J.F., and Serhan, C.N. (1996) Activation of human monocytes and the acute monocytic leukemia cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4: evidence for differential Ca²⁺ mobilization. *J. Immunol.* **157**, 2149–2154.
 29. Godson, C., Mitchell, S., Harvey, K., Petasis, N.A., Hogg, N., and Brady, H.R. (2000) Cutting edge: lipoxins rapidly stimulate nonphagocytic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. *J. Immunol.* **164**, 1663–1667.
 30. Ramstedt, U., Serhan, C.N., Nicolaou, K.C., Webber, S.E., Wigzell, H., and Samuelsson, B. (1987) Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: studies on stereospecificity of inhibition and mode of action. *J. Immunol.* **138**, 266–270.
 31. Ariel, A., Chiang, N., Arita, M., Petasis, N.A., and Serhan, C.N. (2003) Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. *J. Immunol.* **170**, 6266–6272.
 32. Aliberti, J., Hieny, S., Reis e Sousa, C., Serhan, C.N., and Sher, A. (2002) Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. *Nat. Immunol.* **3**, 76–82.
 33. Machado, F.S., Johndrow, J.E., Esper, L., Dias, A., Bafica, A., Serhan, C.N., and Aliberti, J. (2006) Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. *Nat. Med.* **12**, 330–334.
 34. Soyombo, O., Spur, B.W., and Lee, T.H. (1994) Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. *Allergy* **49**, 230–234.
 35. Bandeira-Melo, C., Bozza, P.T., Diaz, B.L., Cordeiro, R.S., Jose, P.J., Martins, M.A., and Serhan, C.N. (2000) Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. *J. Immunol.* **164**, 2267–2271.
 36. Scalia, R., Gefen, J., Petasis, N.A., Serhan, C.N., and Lefer, A.M. (1997) Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. *Proc. Natl. Acad. Sci. U. S. A.* **94**, 9967–9972.
 37. Nascimento-Silva, V., Arruda, M.A., Barja-Fidalgo, C., Villela, C.G., and Fierro, I.M. (2005) Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. *Am. J. Physiol. Cell. Physiol.* **289**, C557–563.
 38. Biteman, B., Hassan, I.R., Walker, E., Leedom, A.J., Dunn, M., Seta, F., Laniado-Schwartzman, M., and Gronert, K. (2007) Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. *FASEB J.* **21(9)**, 2257–2266.

39. Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J., and Fiore, S. (2000) Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. *J. Immunol.* **164**, 2660–2666.
40. Planaguma, A., Titos, E., Lopez-Parra, M., Gaya, J., Pueyo, G., Arroyo, V., and Claria, J. (2002) Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. *FASEB J.* **16**, 1937–1939.
41. Karp, C.L., Flick, L.M., Park, K.W., Softic, S., Greer, T.M., Keledjian, R., Yang, R., Uddin, J., Guggino, W.B., Atabani, S.F., Belkaid, Y., Xu, Y., Whitsett, J.A., Accurso, F.J., Wills-Karp, M., and Petasis, N.A. (2004) Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. *Nat. Immunol.* **5**, 388–392.
42. Bonnans, C., Fukunaga, K., Levy, M.A., and Levy, B.D. (2006) Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. *Am. J. Pathol.* **168**, 1064–1072.
43. Levy, B.D., De Sanctis, G.T., Devchand, P.R., Kim, E., Ackerman, K., Schmidt, B.A., Szczeklik, W., Drazen, J.M., and Serhan, C.N. (2002) Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). *Nat. Med.* **8**, 1018–1023.
44. Fiorucci, S., de Lima, O.M., Jr., Mencarelli, A., Palazzetti, B., Distrutti, E., McKnight, W., Dickey, M., Ma, L., Romano, M., Morelli, A., and Wallace, J.L. (2002) Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. *Gastroenterology* **123**, 1598–1606.
45. Chiang, N., Takano, T., Arita, M., Watanabe, S., and Serhan, C.N. (2003) A novel rat lipoxin A4 receptor that is conserved in structure and function. *Br. J. Pharmacol.* **139**, 89–98.
46. Fiorucci, S., Wallace, J.L., Mencarelli, A., Distrutti, E., Rizzo, G., Farneti, S., Morelli, A., Tseng, J.L., Suramanyam, B., Guilford, W.J., and Parkinson, J.F. (2004) A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 15736–15741.
47. Gewirtz, A.T., Collier-Hyams, L.S., Young, A.N., Kucharzik, T., Guilford, W.J., Parkinson, J.F., Williams, I.R., Neish, A.S., and Madara, J.L. (2002) Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. *J. Immunol.* **168**, 5260–5267.
48. Serhan, C.N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S.P., Stahl, G.L., Merched, A., Petasis, N.A., Chan, L., and Van Dyke, T.E. (2003) Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. *J. Immunol.* **171**, 6856–6865.
49. Schottelius, A.J., Giesen, C., Asadullah, K., Fierro, I.M., Colgan, S.P., Bauman, J., Guilford, W., Perez, H.D., and Parkinson, J.F. (2002) An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. *J. Immunol.* **169**, 7063–7070.
50. Gronert, K. (2005) Lipoxins in the eye and their role in wound healing. *Prostaglandins Leukot. Essent. Fatty Acids* **73**, 221–229.
51. Devchand, P.R., Schmidt, B.A., Primo, V.C., Zhang, Q.Y., Arnaout, M.A., Serhan, C.N., and Nikolic, B. (2005) A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils. *FASEB J.* **19**, 203–210.
52. Fiore, S., Ryeom, S.W., Weller, P.F., and Serhan, C.N. (1992) Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. *J. Biol. Chem.* **267**, 16168–16176.
53. Fiore, S., Romano, M., Reardon, E.M., and Serhan, C.N. (1993) Induction of functional lipoxin A4 receptors in HL-60 cells. *Blood* **81**, 3395–3403.
54. Gronert, K., Martinsson-Niskanen, T., Ravasi, S., Chiang, N., and Serhan, C.N. (2001) Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. *Am. J. Pathol.* **158**, 3–9.
55. Fiore, S., Maddox, J.F., Perez, H.D., and Serhan, C.N. (1994) Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. *J. Exp. Med.* **180**, 253–260.
56. Murphy, P.M., Ozcelik, T., Kenney, R.T., Tiffany, H.L., McDermott, D., and Francke, U. (1992) A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. *J. Biol. Chem.* **267**, 7637–7643.
57. Bao, L., Gerard, N.P., Eddy, R.L., Jr., Shows, T.B., and Gerard, C. (1992) Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. *Genomics* **13**, 437–440.
58. Ye, R.D., Cavanagh, S.L., Quehenberger, O., Prossnitz, E.R., and Cochrane, C.G. (1992) Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. *Biochem. Biophys. Res. Commun.* **184**, 582–589.
59. Perez, H.D., Holmes, R., Kelly, E., McClary, J., and Andrews, W.H. (1992) Cloning of a cDNA encoding a receptor related to the formyl peptide receptor of human neutrophils. *Gene* **118**, 303–304.
60. Nomura, H., Nielsen, B.W., and Matsushima, K. (1993) Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. *Int. Immunol.* **5**, 1239–1249.
61. Brink, C., Dahlen, S.E., Drazen, J., Evans, J.F., Hay, D.W., Nicosia, S., Serhan, C.N., Shimizu, T., and Yokomizo, T. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. *Pharmacol. Rev.* **55**, 195–227.
62. Chiang, N., Serhan, C.N., Dahlen, S.E., Drazen, J.M., Hay, D.W., Rovati, G.E., Shimizu, T., Yokomizo, T., and Brink, C. (2006) The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. *Pharmacol.*

- Rev.* **58**, 463–487.
63. Sahagun-Ruiz, A., Colla, J.S., Juhn, J., Gao, J.L., Murphy, P.M., and McDermott, D.H. (2001) Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. *Genes Immun.* **2**, 335–342.
 64. Takano, T., Fiore, S., Maddox, J.F., Brady, H.R., Petasis, N.A., and Serhan, C.N. (1997) Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. *J. Exp. Med.* **185**, 1693–1704.
 65. Gao, J.L., Chen, H., Filie, J.D., Kozak, C.A., and Murphy, P.M. (1998) Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse. *Genomics* **51**, 270–276.
 66. Vaughn, M.W., Proske, R.J., and Haviland, D.L. (2002) Identification, cloning, and functional characterization of a murine lipoxin A4 receptor homologue gene. *J. Immunol.* **169**, 3363–3369.
 67. Devchand, P.R., Arita, M., Hong, S., Bannenberg, G., Moussignac, R.L., Gronert, K., and Serhan, C.N. (2003) Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. *FASEB J.* **17**, 652–659.
 68. Kang, Y., Taddeo, B., Varai, G., Varga, J., and Fiore, S. (2000) Mutations of serine 236-237 and tyrosine 302 residues in the human lipoxin A4 receptor intracellular domains result in sustained signaling. *Biochemistry* **39**, 13551–13557.
 69. Chiang, N., Fierro, I.M., Gronert, K., and Serhan, C.N. (2000) Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. *J. Exp. Med.* **191**, 1197–1208.
 70. Le, Y., Ye, R.D., Gong, W., Li, J., Iribarren, P., and Wang, J.M. (2005) Identification of functional domains in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis. *FEBS J.* **272**, 769–778.
 71. Maddox, J.F., Hachicha, M., Takano, T., Petasis, N.A., Fokin, V.V., and Serhan, C.N. (1997) Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. *J. Biol. Chem.* **272**, 6972–6978.
 72. de Paulis, A., Montuori, N., Prevede, N., Fiorentino, I., Rossi, F.W., Visconte, V., Rossi, G., Marone, G., and Ragno, P. (2004) Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. *J. Immunol.* **173**, 5739–5748.
 73. Yang, D., Chen, Q., Le, Y., Wang, J.M., and Oppenheim, J.J. (2001) Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. *J. Immunol.* **166**, 4092–4098.
 74. Gronert, K., Gewirtz, A., Madara, J.L., and Serhan, C.N. (1998) Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. *J. Exp. Med.* **187**, 1285–1294.
 75. Le, Y., Hu, J., Gong, W., Shen, W., Li, B., Dunlop, N.M., Halverson, D.O., Blair, D.G., and Wang, J.M. (2000) Expression of functional formyl peptide receptors by human astrocytoma cell lines. *J. Neuroimmunol.* **111**, 102–108.
 76. Ying, G., Iribarren, P., Zhou, Y., Gong, W., Zhang, N., Yu, Z.X., Le, Y., Cui, Y., and Wang, J.M. (2004) Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. *J. Immunol.* **172**, 7078–7085.
 77. Koczulla, R., von Degenfeld, G., Kupatt, C., Krotz, F., Zahler, S., Gloe, T., Issbrucker, K., Unterberger, P., Zaiou, M., Lebherz, C., Karl, A., Raake, P., Pfosser, A., Boekstegers, P., Welsch, U., Hiemstra, P.S., Vogelmeier, C., Gallo, R.L., Clauss, M., and Bals, R. (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J. Clin. Invest.* **111**, 1665–1672.
 78. Perretti, M., Chiang, N., La, M., Fierro, I.M., Marullo, S., Getting, S.J., Solito, E., and Serhan, C.N. (2002) Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. *Nat. Med.* **8**, 1296–1302.
 79. Scannell, M., Flanagan, M.B., deStefani, A., Wynne, K.J., Cagney, G., Godson, C., and Maderna, P. (2007) Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. *J. Immunol.* **178**, 4595–4605.
 80. Blasi, F. (1997) uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? *Immunol. Today.* **18**, 415–417.
 81. Mondino, A. and Blasi, F. (2004) uPA and uPAR in fibrinolysis, immunity and pathology. *Trends Immunol.* **25**, 450–455.
 82. Resnati, M., Pallavicini, I., Wang, J.M., Oppenheim, J., Serhan, C.N., Romano, M., and Blasi, F. (2002) The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 1359–1364.
 83. Mazzieri, R., D'Alessio, S., Kenmoe, R.K., Ossowski, L., and Blasi, F. (2006) An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. *Mol. Biol. Cell* **17**, 367–378.
 84. Stone, M.J. (1990) Amyloidosis: a final common pathway for protein deposition in tissues. *Blood* **75**, 531–545.
 85. Su, S.B., Gong, W., Gao, J.L., Shen, W., Murphy, P.M., Oppenheim, J.J., and Wang, J.M. (1999) A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. *J. Exp. Med.* **189**, 395–402.
 86. He, R., Sang, H., and Ye, R.D. (2003) Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor,

- FPRL1/LXA4R. *Blood* **101**, 1572–1581.
87. Tiffany, H.L., Lavigne, M.C., Cui, Y.H., Wang, J.M., Leto, T.L., Gao, J.L., and Murphy, P.M. (2001) Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. *J. Biol. Chem.* **276**, 23645–23652.
88. Yazawa, H., Yu, Z.X., Takeda, Le, Y., Gong, W., Ferrans, V.J., Oppenheim, J.J., Li, C.C., and Wang, J.M. (2001) Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. *FASEB J.* **15**, 2454–2462.
89. Peyrin, J.M., Lasmezas, C.I., Haik, S., Tagliavini, F., Salmona, M., Williams, A., Richie, D., Deslys, J.P., and Dormont, D. (1999) Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. *Neuroreport* **10**, 723–729.
90. Le, Y., Yazawa, H., Gong, W., Yu, Z., Ferrans, V.J., Murphy, P.M., and Wang, J.M. (2001) The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. *J. Immunol.* **166**, 1448–1451.
91. Hashimoto, Y., Niikura, T., Tajima, H., Yasukawa, T., Sudo, H., Ito, Y., Kita, Y., Kawasumi, M., Kouyama, K., Doyu, M., Sobue, G., Koide, T., Tsuji, S., Lang, J., Kurokawa, K., and Nishimoto, I. (2001) A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 6336–6341.
92. Mitchell, S., Thomas, G., Harvey, K., Cottell, D., Reville, K., Berlasconi, G., Petasis, N.A., Erwig, L., Rees, A.J., Savill, J., Brady, H.R., and Godson, C. (2002) Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. *J. Am. Soc. Nephrol.* **13**, 2497–2507.
93. Fierro, I.M., Kutok, J.L., and Serhan, C.N. (2002) Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). *J. Pharmacol. Exp. Ther.* **300**, 385–392.
94. Elagoz, A., Henderson, D., Babu, P.S., Salter, S., Grahames, C., Bowers, L., Roy, M.O., Laplante, P., Grazzini, E., Ahmad, S., and Lembo, P.M. (2004) A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor. *Br. J. Pharmacol.* **141**, 37–46.
95. Chen, Q., Wade, D., Kurosaka, K., Wang, Z.Y., Oppenheim, J.J., and Yang, D. (2004) Temporin A and related frog antimicrobial peptides use formyl peptide receptor-like 1 as a receptor to chemoattract phagocytes. *J. Immunol.* **173**, 2652–2659.
96. Le, Y., Murphy, P.M., and Wang, J.M. (2002) Formyl-peptide receptors revisited. *Trends Immunol.* **23**, 541–548.
97. Fu, H., Karlsson, J., Bylund, J., Movitz, C., Karlsson, A., and Dahlgren, C. (2006) Ligand recognition and activation of formyl peptide receptors in neutrophils. *J. Leukoc. Biol.* **79**, 247–256.
98. Bae, Y.S., Lee, H.Y., Jo, E.J., Kim, J.I., Kang, H.K., Ye, R.D., Kwak, J.Y., and Ryu, S.H. (2004) Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. *J. Immunol.* **173**, 607–614.
99. Burli, R.W., Xu, H., Zou, X., Muller, K., Golden, J., Frohn, M., Adlam, M., Plant, M.H., Wong, M., McElvain, M., Regal, K., Viswanadhan, V.N., Tagari, and P., Hungate, R. (2006) Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. *Bioorg. Med. Chem. Lett.* **16**, 3713–3718.
100. Bonnans, C., Mainprice, B., Chanez, P., Bousquet, J., and Urbach, V. (2003) Lipoxin A4 stimulates a cytosolic Ca²⁺ increase in human bronchial epithelium. *J. Biol. Chem.* **278**, 10879–10884.
101. Bae, Y.S., Park, J.C., He, R., Ye, R.D., Kwak, J.Y., Suh, P.G., and Ho Ryu, S. (2003) Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH₂ or lipoxin A4 in human neutrophils. *Mol. Pharmacol.* **64**, 721–730.
102. Levy, B.D., Fokin, V.V., Clark, J.M., Wakelam, M.J., Petasis, N.A., and Serhan, C.N. (1999) Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. *FASEB J.* **13**, 903–911.
103. Kim, Y., Lee, B.D., Kim, O., Bae, Y.S., Lee, T., Suh, P.G., and Ryu, S.H. (2006) Pituitary adenylate cyclase-activating polypeptide 27 is a functional ligand for formyl peptide receptor-like 1. *J. Immunol.* **176**, 2969–2975.
104. Wu, S.H., Wu, X.H., Lu, C., Dong, L., and Chen, Z.Q. (2006) Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. *Am. J. Respir. Cell Mol. Biol.* **34**, 65–72.
105. Maderna, P., Cottell, D.C., Berlasconi, G., Petasis, N.A., Brady, H.R., and Godson, C. (2002) Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. *Am. J. Pathol.* **160**, 2275–2283.
106. Cezar-de-Mello, P.F., Nascimento-Silva, V., Villela, C.G., and Fierro, I.M. (2006) Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. *Oncogene* **25**, 122–129.
107. Sodin-Semrl, S., Spagnolo, A., Mikus, R., Barbaro, B., Varga, J., and Fiore, S. (2004) Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. *Int. J. Immunopathol. Pharmacol.* **17**, 145–156.
108. Schaldach, C.M., Riby, J., and Bjeldanes, L.F. (1999) Lipoxin A4: a new class of ligand for the Ah receptor. *Biochemistry* **38**, 7594–7600.
109. Badr, K.F., DeBoer, D.K., Schwartzberg, M., and Serhan, C.N. (1989) Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. *Proc.*

- Natl. Acad. Sci. U. S. A.* **86**, 3438–3442.
110. McMahon, B., Stenson, C., McPhillips, F., Fanning, A., Brady, H.R., and Godson, C. (2000) Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. *J. Biol. Chem.* **275**, 27566–27575.

This article should be cited as follows:

Romano, M., Recchia, I., and Recchiuti, A. (2007) Lipoxin receptors. *TheScientificWorldJOURNAL* **7**, 1393–1412. DOI 10.1100/tsw.2007.186.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

